clinical trial · NCT07511010
Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets
Chipscreen Biosciences, Ltd.·phase1·completed·n = 28
T2DM (Type 2 Diabetes Mellitus)Chiglitazar/Metformin extended-release tablets under fasting conditionsChiglitazar/Metformin extended-release tablets after a high-fat mealmultiple-dose of Chiglitazar/Metformin extended-release tablets
brief summary
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants. The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
started
Sep 10, 2026
primary completion
Oct 22, 2026
completion
Oct 25, 2026
last updated
Nov 5, 2026
official title
A Phase I Clinical Study to Assess the Food Effect and Multiple Dose Pharmacokinetic of Chiglitazar/Metformin Extended-Release Fixed Dose Combination Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol